Browse MYC

Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleoplasm Nucleus, nucleolus
Domain PF00010 Helix-loop-helix DNA-binding domain
PF02344 Myc leucine zipper domain
PF01056 Myc amino-terminal region
Function

Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000).

> Gene Ontology
 
Biological Process GO:0000723 telomere maintenance
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001933 negative regulation of protein phosphorylation
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0006091 generation of precursor metabolites and energy
GO:0006112 energy reserve metabolic process
GO:0006338 chromatin remodeling
GO:0006875 cellular metal ion homeostasis
GO:0006879 cellular iron ion homeostasis
GO:0007050 cell cycle arrest
GO:0007219 Notch signaling pathway
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0015669 gas transport
GO:0015671 oxygen transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016055 Wnt signaling pathway
GO:0030099 myeloid cell differentiation
GO:0030224 monocyte differentiation
GO:0031098 stress-activated protein kinase signaling cascade
GO:0032200 telomere organization
GO:0032204 regulation of telomere maintenance
GO:0032844 regulation of homeostatic process
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032873 negative regulation of stress-activated MAPK cascade
GO:0033044 regulation of chromosome organization
GO:0034644 cellular response to UV
GO:0035239 tube morphogenesis
GO:0035690 cellular response to drug
GO:0042326 negative regulation of phosphorylation
GO:0042493 response to drug
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043409 negative regulation of MAPK cascade
GO:0044346 fibroblast apoptotic process
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045655 regulation of monocyte differentiation
GO:0045656 negative regulation of monocyte differentiation
GO:0045786 negative regulation of cell cycle
GO:0045862 positive regulation of proteolysis
GO:0046916 cellular transition metal ion homeostasis
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048147 negative regulation of fibroblast proliferation
GO:0048754 branching morphogenesis of an epithelial tube
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051302 regulation of cell division
GO:0051403 stress-activated MAPK cascade
GO:0051782 negative regulation of cell division
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055072 iron ion homeostasis
GO:0055076 transition metal ion homeostasis
GO:0060070 canonical Wnt signaling pathway
GO:0060249 anatomical structure homeostasis
GO:0060485 mesenchyme development
GO:0060562 epithelial tube morphogenesis
GO:0060675 ureteric bud morphogenesis
GO:0060993 kidney morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070303 negative regulation of stress-activated protein kinase signaling cascade
GO:0071214 cellular response to abiotic stimulus
GO:0071478 cellular response to radiation
GO:0071482 cellular response to light stimulus
GO:0071897 DNA biosynthetic process
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072074 kidney mesenchyme development
GO:0072075 metanephric mesenchyme development
GO:0072078 nephron tubule morphogenesis
GO:0072080 nephron tubule development
GO:0072088 nephron epithelium morphogenesis
GO:0072111 cell proliferation involved in kidney development
GO:0072131 kidney mesenchyme morphogenesis
GO:0072132 mesenchyme morphogenesis
GO:0072133 metanephric mesenchyme morphogenesis
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0072185 metanephric cap development
GO:0072186 metanephric cap morphogenesis
GO:0072203 cell proliferation involved in metanephros development
GO:0072215 regulation of metanephros development
GO:0072216 positive regulation of metanephros development
GO:0090094 metanephric cap mesenchymal cell proliferation involved in metanephros development
GO:0090095 regulation of metanephric cap mesenchymal cell proliferation
GO:0090096 positive regulation of metanephric cap mesenchymal cell proliferation
GO:0090183 regulation of kidney development
GO:0090184 positive regulation of kidney development
GO:0198738 cell-cell signaling by wnt
GO:1901722 regulation of cell proliferation involved in kidney development
GO:1901724 positive regulation of cell proliferation involved in kidney development
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902532 negative regulation of intracellular signal transduction
GO:1903131 mononuclear cell differentiation
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1904837 beta-catenin-TCF complex assembly
GO:2000027 regulation of organ morphogenesis
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000278 regulation of DNA biosynthetic process
GO:2000573 positive regulation of DNA biosynthetic process
GO:2001020 regulation of response to DNA damage stimulus
GO:2001022 positive regulation of response to DNA damage stimulus
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0008134 transcription factor binding
GO:0070491 repressing transcription factor binding
GO:0070888 E-box binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04110 Cell cycle
hsa04151 PI3K-Akt signaling pathway
hsa04310 Wnt signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04630 Jak-STAT signaling pathway
hsa04919 Thyroid hormone signaling pathway
Reactome R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-4411364: Binding of TCF/LEF
R-HSA-4086398: Ca2+ pathway
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-195253: Degradation of beta-catenin by the destruction complex
R-HSA-5688426: Deubiquitination
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-201722: Formation of the beta-catenin
R-HSA-69206: G1/S Transition
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-168256: Immune System
R-HSA-428359: Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-392499: Metabolism of proteins
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-597592: Post-translational protein modification
R-HSA-4641265: Repression of WNT target genes
R-HSA-69242: S Phase
R-HSA-2173796: SMAD2/SMAD3
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-8866911: TFAP2 (AP-2) family regulates transcription of cell cycle factors
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MYC and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28126925Acute Myeloid LeukemiaInhibit immunity (T cell function)MUC1 induces increased expression of c-myc in EVs that induces proliferation in the target MDSC population via downstream effects on cell cycle proteins.
26966191Leukemia; LymphomaInhibit immunity (T cell function)MYC inactivation in mouse tumors down-regulated CD47 and PD-L1 expression and enhanced the antitumor immune response.
26355571AIDS-Related Diffuse Large B-cell LymphomaInhibit immunity (T cell function)When we examined the relationship between stromal immune cells and tumor molecular characteristics, stromal FOXP3+ Treg cells were found to be positively associated with tumor expression of p53 and cMYC, and inversely associated with BCL6.
22588558Nasopharyngeal CarcinomaInhibit immunityThese findings raise the possibility that c-Myc activation in nasopharyngeal carcinoma (NPC) might antagonise the effect of LMP1 on HLA class I expression thus contributing to immune escape of tumour cells.
29195074Non-small cell lung carcinomaInhibit immunity (T and NK cell function); immunotherapy targetMYC is an oncogene. Co-activation of MYC and KRAS promotes CCL9 and IL-23 which enhances recruitment of macrophage, angiogenesis PD-L1-dependent exclusion of T and B cells, exclusion of adaptive T and B cells and NK cells. Thus, promotes inflammation, angiogenesis and immune suppression. Inhibition of MYC reverse immunosuppression and promotes tumor regression via promotion of return of NK cells.
17419945Burkitt LymphomaInhibit immunity (T cell function)Yet, it had remained open whether nonimmunogenicity is the default phenotype when EBNA2 and LMP1 are switched off, or whether c-MYC actively contributes to immunosuppression. We provide evidence also for the latter by showing that c-MYC down-regulates genes of the NF-kappaB and interferon pathway in a dose-dependent fashion.
17211884Burkitt LymphomaInhibit immunity (T cell function)Using a cell line in which EBNA2 and c-myc can be regulated at will, we show that c-MYC negatively regulates STAT1, the central player linking the Type-I and Type-II interferon response. Switching off c-myc expression leads to STAT1 induction through a direct and indirect mechanism involving induction of Type-I interferons. c-MYC thus masks an interferon-inducing activity in these cells.
24890832breast carcinomaInhibit immunity (T&NK cell function); resistant to immunotherapyHence, tumors appear to be "addicted" to MYC because of both tumor cell-intrinsic, cell-autonomous and host-dependent, immune cell-dependent mechanisms.
24883121metastatic disease indicatorInhibit immunity (T cell function); resistant to immunotherapyDynamic planar imaging of Wistar rats with 111In-DTPA-nanobodies revealed that untagged nanobodies showed a 70% drop in kidney accumulation compared to Myc-His-tagged nanobodies at 50 min p.i..
29596783multiple cancer typesInhibit immunityUsing computational approaches, we define genomic and proteomic features associated with MYC and the PMN across the 33 cancers of The Cancer Genome Atlas.
29757193Triple-Negative Breast CarcinomaInhibit immunityMechanistically, Eya3 utilizes its Thr phosphatase activity to dephosphorylate Myc at pT58, resulting in a stabilized form. We show that Myc is required for Eya3-mediated increases in PD-L1, and that rescue of PD-L1 in Eya3-knockdown cells restores tumor progression.
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.59 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4490.186
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2550.924
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5910.762
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.360.515
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6710.774
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0390.99
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1340.775
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1960.919
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0070.997
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2480.874
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2590.914
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4420.0123
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYC
Namev-myc avian myelocytomatosis viral oncogene homolog
Aliases c-Myc; bHLHe39; MYCC; MRTLC; avian myelocytomatosis viral oncogene homolog; class E basic helix-loop-helix p ......
Chromosomal Location8q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYC collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MYC.
ID Name Drug Type Targets #Targets
DB08813NadroparinSmall MoleculeFOS, MYC, SELP, SERPINC14